The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs

This publication has 9 references indexed in Scilit:

• Pharmacological Profile of a New, Potent, and Long-Acting Gonadotropin-Releasing Hormone Antagonist: Degarelix
  The Journal of Pharmacology and Experimental Therapeutics, 2002
• Clinical and Experimental Progression of a New Model of Human Prostate Cancer and Therapeutic Approach
  The American Journal of Pathology, 2001
• GnRH Antagonists: A New Generation of Long Acting Analogues Incorporatingp-Ureido-phenylalanines at Positions 5 and 6
  Journal of Medicinal Chemistry, 2000
• The LHRH antagonist Cetrorelix: a review
  Human Reproduction Update, 2000
• Development of GnRH Antagonists for Prostate Cancer: New Approaches to Treatment
  The Oncologist, 2000
• Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
  Computer Methods and Programs in Biomedicine, 1998
• Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer
  The Prostate, 1994
• An introduction to mixed effect modeling: Concepts, definitions, and justification
  Journal of Pharmacokinetics and Biopharmaceutics, 1991
• Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
  Proceedings of the National Academy of Sciences, 1991